Compare Neurocrine Biosciences Inc (NBIX) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Oxford Lane Capital Corp — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Oxford Lane Capital Corp trades at $9.67 (market cap $942.56M). The key difference: Neurocrine Biosciences Inc is far larger — about 16.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 24.96% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | OXLC | |
|---|---|---|
Market Cap | $15.77B | $942.56M |
Sector | Health | Financials |
52-Week High | $185.50 | $17.73 |
52-Week Low | $123.10 | $8.15 |
Enterprise Value | $15.78B | — |
Dividend Yield | — | 24.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
OXLC trades at $9.61, down 0.52% on the day, with a bullish technical signal supported by moving averages but mixed earnings performance. Recent quarters show significant misses versus expectations, including a large loss in Q1 2026, though the company maintains a steady dividend payout. Net income margin is exceptionally high at 100.85% for 2026, but this follows negative revenue, while 2025 showed positive net income of $48.46M. The P/B ratio of 0.91 suggests the stock trades below book value.
Outlook is cautious due to volatile earnings and high yield sustainability concerns, with analyst sentiment split evenly between buy and sell ratings. Key risks include earnings instability and reliance on financing cash flow, but the discount to book value and consistent dividends may appeal to income-focused investors amid bullish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
